American Association for Cancer Research
19406207capr170264-sup-188038_2_supp_4434319_p0jr49.pdf (493.66 kB)

Figure S2B from Chemoprevention of Preclinical Breast and Lung Cancer with the Bromodomain Inhibitor I-BET 762

Download (493.66 kB)
journal contribution
posted on 2023-04-03, 22:09 authored by Di Zhang, Ana S. Leal, Sarah Carapellucci, Kayla Zydeck, Michael B. Sporn, Karen T. Liby

Suppl Fig 2B: Effects of I-BET 762 on immune cells in PyMT mice after 9 weeks of treatment.


Breast Cancer Research Foundation

Pharmacological Sciences Training



Breast cancer and lung cancer remain the top two leading causes of cancer-related deaths in women. Because of limited success in reducing the high mortality of these diseases, new drugs and approaches are desperately needed. Cancer prevention is one such promising strategy that is effective in both preclinical and clinical studies. I-BET 762 is a new bromodomain inhibitor that reversibly targets BET (bromodomain and extraterminal) proteins and impairs their ability to bind to acetylated lysines on histones, thus interrupting downstream transcription. This inhibitor has anti-inflammatory effects and induces growth arrest in many cancers and is currently under clinical trials for treatment of cancer. However, few studies have investigated the chemopreventive effects of bromodomain inhibitors. Here, we found that I-BET 762 significantly delayed tumor development in preclinical breast and lung cancer mouse models. This drug not only induced growth arrest and downregulated c-Myc, pSTAT3, and pERK protein expression in tumor cells in vitro and in vivo but also altered immune populations in different organs. These results demonstrate the promising potential of using I-BET 762 for cancer prevention and suggest the striking effects of I-BET 762 are the result of targeting both tumor cells and the tumor microenvironment. Cancer Prev Res; 11(3); 143–56. ©2017 AACR.

Usage metrics

    Cancer Prevention Research



    Ref. manager